Artiva grants director Daniels 16,250 options

Artiva Biotherapeutics granted director Brian Daniels stock options for 16,250 shares at a $10.42 exercise price, vesting by the 2027 annual meeting.

Available on EDGAR 09/14/2026 - 04:04 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of stock options for 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and expire on September 9, 2036.

The options vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. After this grant, Daniels holds stock options covering 16,250 shares directly. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider DANIELS BRIAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Holdings Before and After: Director Stock Option (Right to Buy), 0 to 16,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Stock options granted: 16,250 shares Exercise price: $10.42 per share Expiration date: September 9, 2036 +2 more

5 metrics

Stock options granted 16,250 shares Director stock options granted to Brian Daniels on September 10, 2026

Exercise price $10.42 per share Exercise price of options granted to Brian Daniels

Expiration date September 9, 2036 Expiration of the option grant to Brian Daniels

Underlying common shares 16,250 shares Common stock underlying the granted options

Post-grant option holdings 16,250 shares Options held directly by Brian Daniels after the reported grant

Key Terms

stock options, exercise price, expiration date, annual stockholder meeting

4 terms

stock options financial

"director Brian Daniels received a grant of stock options for 16,250 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The options have an exercise price of $10.42 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"with an exercise price of $10.42 per share and an expiration date of September 9, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual stockholder meeting regulatory

"will vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV disclose for director Brian Daniels?

Artiva Biotherapeutics disclosed that director Brian Daniels received a grant of stock options for 16,250 shares of common stock on September 10, 2026, with an exercise price of $10.42 per share and an expiration date of September 9, 2036.

What is the exercise price of the new stock options reported by ARTV?

The stock options granted to director Brian Daniels have an exercise price of $10.42 per share, allowing him to purchase Artiva Biotherapeutics common stock at that price if he exercises the options before they expire.

When do Brian Daniels’ ARTV stock options vest?

The options will vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting, as disclosed in the vesting footnote.

How many ARTV shares are covered by Brian Daniels’ new option grant?

The new option grant to Brian Daniels covers 16,250 shares of Artiva Biotherapeutics common stock. Following this grant, he directly holds options for 16,250 shares according to the filing.

Are Brian Daniels’ ARTV option grants under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is associated with this option grant to director Brian Daniels.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANIELS BRIAN

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)